May 20, 2013
GREENWICH, CT and SAN FRANCISCO, CA — Great Point Partners (“GPP”) announced the addition of seasoned medical device executive Robert W. Thomas to the firm’s CEO Advisory Board. CEO Advisory Board members at Great Point Partners act as Operating Chairmen and Lead Directors of the firm’s private equity portfolio companies.
From March, 2000 through December, 2006, Mr. Thomas served as President and CEO of FoxHollow Technologies, having previously served as the company’s Vice President of Operations. Under Mr. Thomas’ leadership, FoxHollow executed one of the most successful product launches in the history of the medical device industry, completed its IPO, and ultimately achieved a market capitalization of more than $1.2 billion prior to its sale to EV3 in 2007.
Mr. Thomas will be working closely with GPP Managing Director Scott R. Davidson to source and execute medical device buyouts, recapitalizations and carve-outs for GPP’s Great Point Partners II (“GPP II”) private equity fund. In addition to joining the GPP CEO Advisory Board, Mr. Thomas will be making a significant personal investment in GPP II. Mr. Thomas and Mr. Davidson are currently working together on an initial investment for GPP II in the medical devices space; the carve-out of a health care products business from within a larger enterprise.
About Great Point Partners
GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. GPP is currently investing from GPP II, which is targeted at $200 million.
Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, pharmaceutical infrastructure, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.
This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.